Immunoengineers are experts who apply principles of engineering to design and optimize immune-based therapies. They work at the intersection of immunology, biotechnology, and bioengineering, developing novel approaches to enhance the immune system's ability to fight diseases. These professionals focus on designing engineered immune cells, such as CAR T-cells, and developing immunotherapies that can more effectively target and destroy cancer cells, pathogens, or other harmful agents. Immunoengineers use cutting-edge technologies, including genetic engineering, synthetic biology, and nanotechnology, to improve immune responses, making treatments more precise and less toxic for patients.
Their work in cancer and infectious disease treatment, immunoengineers are advancing the field of vaccine development by designing immunization strategies that enhance immune memory and response. They are also exploring the use of immune modulation to treat autoimmune diseases and chronic conditions. Immunoengineering is a rapidly evolving field, with researchers constantly pushing the boundaries to create more effective, personalized therapies. Through their interdisciplinary expertise, immunoengineers are making a significant impact on the future of medicine, transforming the way we approach immune system manipulation for therapeutic purposes. Immunoengineers are shaping the future of healthcare by developing innovative immune-based therapies that offer more targeted and effective solutions. Their work continues to revolutionize treatments, offering hope for curing previously untreatable conditions.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia